Lipocine Interest Expense vs Operating Income Analysis
LPCN Stock | USD 5.44 0.12 2.26% |
Lipocine financial indicator trend analysis is infinitely more than just investigating Lipocine recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lipocine is a good investment. Please check the relationship between Lipocine Interest Expense and its Operating Income accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
Interest Expense vs Operating Income
Interest Expense vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lipocine Interest Expense account and Operating Income. At this time, the significance of the direction appears to have no relationship.
The correlation between Lipocine's Interest Expense and Operating Income is 0.0. Overlapping area represents the amount of variation of Interest Expense that can explain the historical movement of Operating Income in the same time period over historical financial statements of Lipocine, assuming nothing else is changed. The correlation between historical values of Lipocine's Interest Expense and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Expense of Lipocine are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Interest Expense i.e., Lipocine's Interest Expense and Operating Income go up and down completely randomly.
Correlation Coefficient | 0.0 |
Relationship Direction | Flat |
Relationship Strength | Insignificant |
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Operating Income
Operating Income is the amount of profit realized from Lipocine operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Lipocine is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Lipocine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lipocine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.At this time, Lipocine's Selling General Administrative is very stable compared to the past year. As of the 19th of April 2024, Sales General And Administrative To Revenue is likely to grow to 46.82, while Tax Provision is likely to drop 411.40.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 5.3M | 4.1M | 15.1M | 15.8M | Cost Of Revenue | 7.7M | 8.6M | 28.7K | 27.2K |
Lipocine fundamental ratios Correlations
Click cells to compare fundamentals
Lipocine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lipocine fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 19.7M | 25.4M | 52.5M | 37.5M | 23.0M | 29.7M | |
Other Current Liab | 449.3K | 1.7M | 1M | 1.1M | 1.2M | 1.5M | |
Total Current Liabilities | 5.0M | 6.6M | 5.6M | 1.7M | 2.6M | 3.4M | |
Total Stockholder Equity | 6.3M | 15.3M | 45.6M | 35.6M | 20.4M | 24.6M | |
Net Debt | (2.6M) | (13.6M) | (639.7K) | (3.1M) | (4.8M) | (5.0M) | |
Retained Earnings | (151.1M) | (172.0M) | (172.7M) | (183.4M) | (199.8M) | (189.8M) | |
Accounts Payable | 1.2M | 1.6M | 1.3M | 600.4K | 1.4M | 798.8K | |
Cash | 9.7M | 19.2M | 3.0M | 3.1M | 4.8M | 9.2M | |
Cash And Short Term Investments | 14.1M | 19.7M | 44.6M | 32.5M | 22.0M | 26.6M | |
Common Stock Total Equity | 2.2K | 3.8K | 7.0K | 8.8K | 10.2K | 10.7K | |
Common Stock Shares Outstanding | 1.5M | 3.3M | 5.1M | 5.2M | 5.3M | 5.5M | |
Liabilities And Stockholders Equity | 19.7M | 25.4M | 52.5M | 37.5M | 23.0M | 29.7M | |
Other Current Assets | 545.9K | 661.3K | 1.5M | 945.3K | 773.4K | 1.0M | |
Other Stockholder Equity | 157.4M | 187.4M | 218.2M | 219.1M | 220.1M | 147.6M | |
Total Liab | 13.4M | 10.0M | 6.9M | 1.9M | 2.6M | 5.1M | |
Total Current Assets | 19.6M | 25.3M | 46.4M | 34.1M | 22.9M | 28.8M | |
Accumulated Other Comprehensive Income | (963.0) | (38.0) | (18.0K) | (20.3K) | 7.3K | 7.6K | |
Common Stock | 3.8K | 7.0K | 8.8K | 8.9K | 8.9K | 9.3K | |
Property Plant Equipment | 19.0K | 3.6K | 7.2K | 131.6K | 118.4K | 124.4K | |
Net Tangible Assets | 6.3M | 15.3M | 45.6M | 35.6M | 41.0M | 27.0M | |
Retained Earnings Total Equity | (138.1M) | (151.1M) | (172.0M) | (172.7M) | (155.4M) | (163.2M) | |
Short Term Investments | 4.3M | 450.0K | 41.7M | 29.4M | 17.3M | 15.1M | |
Capital Surpluse | 147.5M | 157.4M | 187.4M | 218.3M | 251.0M | 143.4M | |
Property Plant And Equipment Net | 3.6K | 0.0 | 7.2K | 131.6K | 116.1K | 63.4K | |
Non Current Assets Total | 27.3K | 23.8K | 6.1M | 3.4M | 139.8K | 132.9K | |
Property Plant And Equipment Gross | 3.6K | 1.1M | 1.2M | 1.3M | 1.3M | 1.4M | |
Net Receivables | 16.5K | 391.0 | 247.3K | 659.9K | 52.3K | 49.6K | |
Net Invested Capital | 13.4M | 20.9M | 47.9M | 35.6M | 20.4M | 27.8M | |
Net Working Capital | 14.7M | 18.7M | 40.8M | 32.5M | 20.2M | 25.5M | |
Short Long Term Debt Total | 7.1M | 5.6M | 2.3M | 17.2K | 15.4K | 14.7K | |
Capital Stock | 3.8K | 7.0K | 8.8K | 8.9K | 8.9K | 7.2K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Lipocine Stock analysis
When running Lipocine's price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share (0.54) | Quarterly Revenue Growth (1.00) | Return On Assets (0.37) | Return On Equity (0.58) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.